2016 International Congress Archives - Page 3 of 207

L-dopa-responsive, diurnally fluctuating auricular tremor with tetrahydrobiopterin (BH4) deficiency

N.K. Iwata, H. Shintaku, S. Shibata, K. Takeda, J. Goto (Tokyo, Japan)
Lack of association between LRRK2 G2385R and cognitive dysfunction in Korean patients with idiopathic Parkinson’s disease

J.H. Hong, Y.K. Kim, J.S. Park, J.E. Lee, M.S. Oh, E.J. Chung, J.Y. Kim, Y.H. Sung, C.H. Lyoo, J.H. Lee, D.Y. Kwon, H.S. Kim, H.W. Shin, S.A. Park, I.S. Park, J.S. Kim, P.H. Lee, S.B. Koh, J.S. Baik, S.J. Kim, H.I. Ma, J.W. Kim, Y.J. Kim (Anyang, Korea)
Lance-Adams syndrome with post-hypoxic myoclonus- physiotherapy intervention

B. Cruz (Long Beach, CA, USA)
LC3 deacetylation by SIRT1 is involved in neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson’s disease

Y. Wu, Y. Guo, S. Dong, X. Cui, Y. Feng, W. Zhao (Shanghai, People's Republic of China)
Lead angle matters: Side effects of deep brain stimulation improved with adjustment of lead angle

M.H. Pourfar, A.Y. Mogilner (New York, NY, USA)
Lessons learned from the Nilotinib trial: Cardio-vascular conditions in parkinsonism

Y. Torres-Yaghi, A. Keys, V. Ellen, S. Ashot, M. Elizabeth, S. Justin, M. Charbel, P. Fernando (Washington, DC, USA)
Lessons-experienced in the creation of a global public-private consortium with the goal of advancing treatments that hold most potential for delayed disease progression in Parkinson’s disease – Critical path for Parkinson’s (CPP)

V.D. Kern, D.T. Stephenson, K. Romero, E. Avilés, S.T. Broadbent, S.P. Arneric, L. Barbieri, S. Ford, A. Roach (Tucson, AZ, USA)
Leukocyte perturbations suggest immune dysregulation in progressive supranuclear palsy

M.C. Schiess, J.O. Suescun, A. Actor, A. Gonzales, K.C. Smith (Houston, TX, USA)
Levodopa impairs learning in healthy young adults: Implications for Parkinson’s disease

P.A. MacDonald, A. Vo, K.N. Seergobin (London, ON, Canada)
Levodopa induced dyskinesia and nicotinergic α4β2 acetylcholin receptor density: A multi-tracer imaging study

J. Brumberg, S. Küsters, G. Marotta, M.M. Reich, F. Steigerwald, A. Buck, J. Volkmann, S. Samnick, I.U. Isaias (Würzburg, Germany)
Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry

W. Poewe, T. Kimber, B. Bermans, P. Odin, A. Antonini, O. Bajenaru, K. Onuk, A. Yegin, L. Bergmann, K.R. Chaudhuri (Innsbruck, Austria)
Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry

K.R. Chaudhuri, Z. Pirtosek, B. Pickut, W. Poewe, F. Valldeoriola, L. Defebvre, R. Jech, P. Odin, C. Winkler, J. Szasz, K. Onuk, A. Yegin, L. Bergmann, A. Antonini (London, United Kingdom)
Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience

E. Pekkonen, J. Lyytinen, O. Lindström, L. Kylänpää, M. Udd (Helsinki, Finland)
Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease – A randomized, crossover infusion study

M. Senek, D. Nyholm (Uppsala, Sweden)
Levodopa-responsive hereditary spastic paraplegia, SPG35, due to FA2H mutations in siblings

Y. Xing, J.R. Friedman (La Jolla, CA, USA)
Levodopa, placebo and rotigotine change biomarker levels for oxidative stress

S. Muhlack, M. Kinkel, L. Herrmann, L. Tönges, T. Müller (Bochum, Germany)
Levodopa/carbidopa intestinal gel treatment in advanced Parkinson’s disease: A long-term observational study

P. Havránková, J. Klempír, M. Fialová, A. Rezková, J. Petrtýl, V. Capek, E. Ruzicka, J. Roth, R. Jech (Praha, Czech Republic)
Levodopa/carbidopa intestinal gel, neuropathy, and B-vitamins – Is there an association?

S. Löns, E. Chorbadgieva, A. Kleimann, D. Dressler, C. Schrader (Hannover, Germany)
Lewy body extracts from Parkinson’s disease brains as models for high-throughput screens of neurotoxicity and α-synuclein spreading from cell-to-cell

E. Bezard, F. Cavaliere, P. Kitchener, E.Y. Pioli, B. Dehay, M. Bourdenx, P. Ramos-Gonzalez, J. Obeso, C. Matute (Bordeaux, France)
Life expectancy and dementia – Two sides of the coin in Parkinson’s disease

S. Tursunov, G. Rakhimbaeva, F. Yunusov, K. Abdukhalimova, R. Agzamov, R. Mirzaev, D. Lutfullaeva, J. Olimov (Tashkent, Uzbekistan)
Life satisfaction in Parkinson’s disease – associated factors

K. Rosqvist, P. Hagell, P. Odin, S. Iwarsson, H. Ekström, M.H. Nilsson (Lund, Sweden)
Localization and functional study of synaptic vesicle protein synaptogyrin-3 (SYNGR3) on dopaminergic neuronal system

L.F. Li, P.W.L. Ho, H.F. Liu, Z.H.M. Tse, C.S.C. Lam, M.C.T. Leung, M.H.W. Kung, D.B. Ramsden, S.W.L. Ho (Hong Kong, People's Republic of China)
Localization of basal ganglia and thalamic damage in dyskinetic cerebral palsy

B.R. Aravamuthan, J.L. Waugh (Boston, MA, USA)
Long term prognosis of functional motor disorders, a case-control follow-up study

J. Gelauff, L. Ludwig, A. Carson, M. Tijssen, J. Stone (Groningen, Netherlands)
Long term recordings of subthalamic ocillatory activity in patients with Parkinson’s disease

W.J. Neumann, F. Staub, A. Horn, J. Schanda, G.H. Schneider, P. Brown, A.A. Kühn (Berlin, Germany)
Long-duration response to levodopa in Parkinson’s disease is independent of disease duration: A prospective study on de novo patients in Ghana

R. Cilia, E. Cereda, M. Amboni, A. Akpalu, F.S. Sarfo, M. Cham, M. Fabbri, G. Pezzoli (Milan, Italy)
Long-latency somatosensory evoked potentials of the subthalamic nucleus

C. Trenado, S. Elben, L. Friggemann, S. Gruhn, S. Groiss, J. Vesper, A. Schnitzler, L. Wojtecki (Düsseldorf, Germany)
Long-term comparative outcomes of functional neurosurgical procedures for treatment of secondary hemidystonia

W.O. Contreras Lopez, A.R.C. Azevedo, M.G. Guilardi, M. San Martin Sepulveda, R.C.R. Martinez, M.J. Teixeira, E.T. Fonoff (São Paulo, Brazil)
Long-term effects of a short inpatient rehabilitation course and peer support in dystonia

K. Martikainen, S. Kinos, R. Marttila (Turku, Finland)
Long-term effects of levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease patients: Dutch multicenter retrospective cohort study

H.R. Moes, J. Groenendal-Laurensse, M. Drent, G. Tissingh, T. van Laar (Groningen, Netherlands)
Long-term effects of pallidal DBS in patients with primary dystonia

P. Krause, S. Völzmann, A. Kupsch, G.H. Schneider, A. Kühn (Berlin, Germany)
Long-term efficacy of safinamide on mood in Parkinsonian patients with fluctuations

C. Cattaneo, E. Mueller, M. Sardina (Bresso, Italy)
Long-term impact of lead poisoning on neurologic function in children and adolescents

N.T. Boyd, M.J. Kuiper, R. Brandsma, T.F. Lawerman, R.J. Lunsing, F. Serrano, C. Olivera, D.A. Sival (Groningen, Netherlands)
Long-term incidence of Parkinson’s disease in rural areas of Finland

J. Isotalo, T. Vahlberg, V. Kaasinen (Turku, Finland)
Long-term responsive deep brain stimulation in Tourette syndrome

R.A. Molina, J.B. Shute, P.J. Rossi, E. Opri, K.D. Foote, M.S. Okun, A. Gunduz (Gainesville, FL, USA)
Long-term results of pallidal deep brain stimulation in a cohort of eight children with isolated dystonia assessed by blinded video rating

P. Krause, K. Lauritsch, A. Lipp, A. Horn, B. Weschke, A. Kupsch, K. Kiening, G.H. Schneider, A. Kühn (Berlin, Germany)
Long-term safety of levodopa-carbidopa intestinal gel from an ongoing, open-label, phase 3 continued access to treatment study in advanced Parkinson’s disease patients

R.L. Rodriguez, C. Zadikoff, A.J. Espay, V.S.C. Fung, C. Hall, W.Z. Robieson, K. Chatamra, S. Eaton, M.F. Facheris, J. Benesh (Orlando, FL, USA)
Longitudinal assessment of caregiver strain in Parkinson’s disease

C.K. Okoro, P. Schmidt, S.S. Wu, J.G. Goldman (Chicago, IL, USA)
Longitudinal assessment of sleep in an incident Parkinson’s disease cohort

S.T. O'Dowd, G.W. Duncan, T.K. Khoo, A.J. Yarnall, R.A. Lawson, D.J. Burn, K.N. Anderson (Newcastle upon Tyne, United Kingdom)
Longitudinal cerebrospinal fluid biomarkers in early Parkinson’s disease and healthy controls

B. Mollenhauer, C.J. Caspell-Garcia, C.S. Coffey, P. Taylor, L.M. Shaw, J.Q. Trojanowski, A. Singleton, M. Frasier, K. Marek, D.R. Galasko (Kassel, Germany)
Longitudinal changes of speech and voice disorders following subthalamic stimulation in Parkinson’s disease patients

T. Tsuboi, H. Watanabe, Y. Tanaka, R. Ohdake, K. Kawabata, K. Hara, M. Ito, M. Hirayama, Y. Fujimoto, Y. Kajita, M. Katsuno, G. Sobue (Nagoya, Japan)
Longitudinal evaluation of motor and non motor symptoms among LRRK2 risk variants

E.W. Lim, X. Deng, H.H. Li, P. Kumar M, Y.L. Ng, Y.L. Lo, E.K. Tan (Singapore, Singapore)
Longitudinal evolution of excessive daytime sleepiness in early Parkinson’s disease

T. Simuni, C. Caspell-Garcia, J. Long, C.S. Coffey, W. Oertel, S. Lasch, K. Marek, On behalf of the PPMI Sleep Working Group (Chicago, IL, USA)
Longitudinal evolution of possible REM sleep behavior disorder in early Parkinson’s disease

W. Oertel, T. Simuni, C. Caspell-Garcia, J. Long, C.S. Coffey, A. Iranzo, G. Mayer, L. Chahine, S. Lasch, K. Marek, On behalf of the PPMI Sleep Working Group (Marburg, Germany)
Longitudinal follow-up of the association of tic disorders with poor academic performance

E. Cubo, C. Gonzalez-Deza, V. Ausin, V. Delgado, S. Saez, X.R. Garcia-Soto, S. Calvo, J. Cordero, J.M. Trejo, J. Macarron, K. Kompoliti (Burgos, Spain)
Longitudinal measurements of cerebrospinal fluid biomarkers in Parkinson’s disease

S. Hall, Y. Surova, A. Öhrfelt, K. Blennow, H. Zetterberg, O. Hansson (Lund, Sweden)
Longterm outcome of cognition following subthalamic deep brain stimulation in Parkinson´s disease

D. Gruber, C. Lisa, A. Kuehn, U. Kopp, G.H. Schneider, A. Kupsch (Beelitz-Heilstätten, Germany)
Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington’s disease gene carriers

H. Wilson, F. Niccolini, S. Haider, T. Reis Marques, G. Pagano, C. Coello, S. Natesan, S. Kapur, E.A. Rabiner, R.N. Gunn, S.J. Tabrizi, M. Politis (London, United Kingdom)
Loss of FBXO7 (PARK15) leads to disturbances in proteasomal function and models parkinsonism-like and pyramidal symptoms in mice

S. Vingill, D. Brockelt, N. Schwedhelm-Domeyer, L. Tatenhorst, S. Goebbels, P. Lingor, K.A. Nave, J. Stegmueller (Goettingen, Germany)
Loss of heart rate variability in ALS: Time and frequency domain assessment

P. Congiu, G. Milioli, G. Borghero, G. Gioi, F. Marrosu, M. Puligheddu, A.L. Goldberger, S. Mariani (Monserratoo, Italy)
Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3beta activity

C.H. Lin, H.I. Lin, M.L. Chen, T.T. Lai, L.P. Cao, M.J. Farrer, R.M. Wu, C.T. Chien (Taipei, Taiwan)
Low cerebrospinal fluid 3,4-dihydroxyphenylacetic acid and 3,4-dihydroxyphenylglycol levels are biomarkers of Parkinsonian disorders, including PSP

A. Stefani, C. Holmes, E. Olivola, Y. Sharabi, D. Goldstein (Rome, Italy)
Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson’s disease subtype

I. Huertas Fernandez, S. Jesus, J.A. Lojo, F.J. Garcia Gomez, M. Caceres Redondo, J.M. Oropesa Ruiz, F. Carrillo, L. Vargas Gonzalez, J.F. Martin Rodriguez, P. Gomez Garre, D. Garcia Solis, P. Mir (Sevilla, Spain)
Lrrk2 alleles modify host response to microbial infections

B. Shutinoski, I. Harmsen, M. Hakimi, Y.Y. Zhou, S. Sad, J.J. Tomlinson, E.G. Brown, M.G. Schlossmacher, CLINT Investigators (Ottawa, ON, Canada)
LRRK2 G2019S mutation carrier with an unusual phenotype: Progressive logopenic aphasia

S. López, A. Pozueta, M. Sierra, R. Quirce, P. Sánchez-Juan, I. González-Aramburu, C. Sánchez-Quintana, J.M. Carril, J. Infante (Santander, Spain)
LRRK2, MAPT and HTRA2 mutations in the pedigree of familial neurodegenerative parkinsonism with cognitive deterioration spanning five generations in a genetically isolated population of south-eastern Moravia, Czech Republic

T. Bartonikova, R. Vodicka, K. Mensikova, R. Vrtel, P. Kanovsky, P. Otruba, M. Vastik, L. Mikulicova, S. Kurcova, P. Jugas, J. Ovecka, L. Sachova, F. Dvorsky (Olomouc, Czech Republic)
LSVT-BIG© case studies: A snapshot of observations

L.A. Dearle (Johannesburg, South Africa)
Lymphocytes have a detrimental effect on motor behavior in the AAV1/2 A53T α-synuclein mouse model of Parkinson’s disease

A.A. Karikari, M. Gehmeyr, E. Ribechini, V. Maltese, J. Volkmann, J.M. Brotchie, J.B. Koprich, M.B. Lutz, C.W. Ip (Würzburg, Germany)
Lysosomal alterations in peripheral blood mononuclear cells of Parkinson’s disease patients

N. Papagiannakis, M. Xilouri, C. Koros, M. Stamelou, R. Antonelou, M. Maniati, D. Papadimitriou, M. Moraitou, H. Michelakakis, L. Stefanis (Chaidari, Greece)